TABLE 2.
Prevalence and composition of coresistance phenotypesa for 10 species of Enterobacteriaceae in 2001
| Organism | No. of isolates | % of isolates pan- susceptibleb | % of isolates resistant to one antimicrobial agent
|
% of isolates resistant to 2 anti- microbial agents | % of isolates resistant to 3 anti- microbial agents | % of isolates pan- resistantc | Most frequent coresistance phenotype(s) (% of total no. of isolates tested) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Ceftazidime | Gentamicin | Levofloxacin | SXT | |||||||
| E. coli | 19,277 | 74.3 | 0.2 | 1.0 | 2.1 | 13.0 | 5.7 | 3.1 | 0.6 | LVX, SXT (3.9); GEN, LVX, SXT (2.7) |
| K. pneumoniae | 7,980 | 82.7 | 1.0 | 0.7 | 1.3 | 4.7 | 4.1 | 3.2 | 2.2 | CTZ, GEN, LVX, SXT (2.2); CTZ, GEN, SXT (1.4) |
| E. aerogenes | 1,727 | 73.4 | 15.6 | 0.4 | 1.3 | 1.0 | 6.0 | 1.8 | 0.6 | CTZ, GEN (4.2); CTZ, GEN, SXT (0.8) |
| E. cloacae | 4,153 | 62.7 | 16.4 | 0.7 | 1.0 | 2.2 | 5.8 | 6.6 | 4.7 | CTZ, GEN, LVX, SXT (4.7); CTZ, GEN, SXT (3.4) |
| C. freundii | 1,238 | 53.1 | 16.2 | 1.5 | 3.0 | 7.6 | 10.7 | 6.0 | 1.9 | LVX, SXT (3.0); CTZ, SXT (2.4) |
| M. morganii | 842 | 57.7 | 6.3 | 0.6 | 1.8 | 5.2 | 13.0 | 9.4 | 6.1 | CTZ, GEN, LVX, SXT (6.1); LVX, SXT (6.0) |
| P. mirabilis | 3,650 | 75.5 | 0.3 | 1.9 | 3.8 | 5.6 | 12.4 | 4.0 | 0.3 | LVX, SXT (6.6); GEN, LVX, SXT (3.5) |
| P. vulgaris | 170 | 88.2 | 1.2 | 1.8 | 0.6 | 8.2 | 1.2 | 0 | 0 | GEN, SXT (1.2) |
| Providencia spp. | 455 | 36.9 | 3.3 | 1.5 | 13.8 | 4.0 | 23.3 | 13.6 | 3.5 | GEN, LVX, SXT (11.2); LVX, SXT (11.2) |
| S. marcescens | 2,345 | 84.2 | 4.4 | 3.2 | 2.0 | 1.6 | 3.5 | 0.9 | 0.2 | CTZ, GEN (1.2); GEN, LVX (0.7) |
a
Phenotypes were determined by using ceftazidime (CTZ), gentamicin (GEN), levofloxacin (LVX), and SXT susceptibility testing data.
b
Pan-susceptible isolates were susceptible to ceftazidime, gentamicin, levofloxacin, and SXT.
c
Pan-resistant isolates were resistant to ceftazidime, gentamicin, levofloxacin, and SXT.